Study Identifies Abnormal Surge of Flu-like Illnesses in March

Modelers try a new approach to gauge the true number of COVID-19 cases in the US by using surveillance data for flu-like illnesses.

Written byKatarina Zimmer
| 5 min read
influenza-like illness ILI surge march coronavirus modeling model pandemic sars-cov-2 infection

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK.COM, DESKCUBE

It’s widely accepted among experts that reported COVID-19 cases—currently around 2.6 million for the US—is a vast underestimate of the actual number of infections by the SARS-CoV-2 coronavirus due to limited testing capacity. But figuring out just how much of an underestimate it is has remained elusive.

A three-person team of researchers estimates that 8.7 million Americans could have been infected with the novel coronavirus between March 8 and 28, a period during which fewer than 120,000 new cases were documented. The findings, published last week (June 22) in Science Translational Medicine, are based on an abnormal surge of flu-like illnesses reported to a federal disease surveillance network in March, which the authors attribute largely to SARS-CoV-2.

“[The study’s] estimate is plausible but on the very high end of what other models and experts say was happening at the time,” says Nicholas Reich, a biostatistician at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies